NEW Clinical Trial of Theracurmin for treatment of Crohn’s Disease
"In May 2020, the Journal of Crohn’s and Colitis published the results of a randomized, double-blinded study performed at five independent medical centres in Japan using Theracurmin for patients with mild-to-moderate active Crohn’s disease.
- Dose: 360 mg per day for 12 weeks.
- The Theracurmin group showed a significant reduction in clinical disease activity.
- Clinical (symptomatic) remission rates in the Theracurmin group were 35% at 4 weeks, 40% at 8 and 12 weeks, with 0% at all stages remission in the placebo group.
- Endoscopic (visual examination) remission rate was 15% in the Theracurmin group, 0% in the placebo group.
- Significant healing of anal lesions (p = 0.017) was observed at week 8 in the Theracurmin group.
- No serious adverse events were observed in either group throughout the study.
Researchers concluded that Theracurmin shows significant clinical and endoscopic efficacy together with a favourable safety profile in patients with active mild-to-moderate Crohn’s disease.
References Sugimoto K, Ikeya K, Bamba S, et al. Highly bioavailable curcumin derivative ameliorates Crohn's disease symptoms: A randomized, double-blind, multicenter study. Journal of Crohn's & Colitis. 2020 May."
Natural Factors • November 19, 2020